iTeos Therapeutics (NASDAQ:ITOS) Shares Down 3.7%

iTeos Therapeutics, Inc. (NASDAQ:ITOS) fell 3.7% during mid-day trading on Friday . The stock traded as low as $14.84 and last traded at $14.93. 119,275 shares traded hands during trading, a decline of 66% from the average session volume of 355,060 shares. The stock had previously closed at $15.50.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ITOS. HC Wainwright boosted their price objective on shares of iTeos Therapeutics from $44.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, May 13th. Wedbush reissued an “outperform” rating and set a $21.00 price objective on shares of iTeos Therapeutics in a research note on Monday, June 17th.

iTeos Therapeutics Trading Down 4.3 %

The business’s 50-day moving average is $15.12 and its two-hundred day moving average is $12.49. The stock has a market capitalization of $536.02 million, a PE ratio of -3.93 and a beta of 1.43.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Friday, May 10th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.05). On average, analysts predict that iTeos Therapeutics, Inc. will post -4.57 EPS for the current year.

Institutional Trading of iTeos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ITOS. Kennedy Capital Management LLC acquired a new position in iTeos Therapeutics in the 1st quarter worth $1,988,000. Public Employees Retirement System of Ohio boosted its position in iTeos Therapeutics by 4.9% in the 1st quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock valued at $532,000 after buying an additional 1,817 shares during the last quarter. Acadian Asset Management LLC purchased a new position in iTeos Therapeutics in the 1st quarter valued at about $3,337,000. Vanguard Group Inc. boosted its position in iTeos Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock valued at $20,468,000 after buying an additional 9,660 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in iTeos Therapeutics by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,877 shares of the company’s stock valued at $94,000 after buying an additional 2,737 shares during the last quarter. 97.16% of the stock is owned by hedge funds and other institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.